Immune checkpoint inhibitors (ICIs) designed to block the programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) pathways have revolutionized lung cancer treatment. The gene discussed is PDCD1; the disease is lung carcinoma.